This study, conducted by the National Cancer Institute funded Community Clinical Oncology Programf is convincing, with a high significance (p<0.001) NP-1 has same efficacy, but a better safety that Pfizer's billion product gabapentin. Said that already repeatedly in the past - and safety is the real issue. From a fundamental view this share price is an insult. If they would have a CEO who really can transform the value, the share price would be higher than $ 6.-
Topaz, say it straightforward, this “Mr Talley” is not a only an incompetent snip, he's an arrant liar who has deceived stockholders for years and for his personal advantage.
Earnings on the 24th.
Should like to add nere, that even the best product, if in the hand of a pharmaceutical illiterate, is as much worth as a snowball in the sun. Apparently this Mr. Talley is such a pip-squeak.
Today looks like a good start...